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Neal K. Lakdawala , MD; Samuel G. Wittekind , MD, MSc; Alexandre C. Pereira, MD, PhD; Daniel L. Jacoby, MD;  
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BACKGROUND: Pathogenic variants in MYBPC3, encoding cardiac MyBP-C (myosin binding protein C), are the most common 
cause of familial hypertrophic cardiomyopathy. A large number of unique MYBPC3 variants and relatively small genotyped 
hypertrophic cardiomyopathy cohorts have precluded detailed genotype-phenotype correlations.
METHODS: Patients with hypertrophic cardiomyopathy and MYBPC3 variants were identified from the Sarcomeric Human 
Cardiomyopathy Registry. Variant types and locations were analyzed, morphological severity was assessed, and time-
event analysis was performed (composite clinical outcome of sudden death, class III/IV heart failure, left ventricular assist 
device/transplant, atrial fibrillation). For selected missense variants falling in enriched domains, myofilament localization and 
degradation rates were measured in vitro.
RESULTS: Among 4756 genotyped patients with hypertrophic cardiomyopathy in Sarcomeric Human Cardiomyopathy Registry, 
1316 patients were identified with adjudicated pathogenic truncating (N=234 unique variants, 1047 patients) or nontruncating 
(N=22 unique variants, 191 patients) variants in MYBPC3. Truncating variants were evenly dispersed throughout the gene, 
and hypertrophy severity and outcomes were not associated with variant location (grouped by 5′–3′ quartiles or by founder 
variant subgroup). Nontruncating pathogenic variants clustered in the C3, C6, and C10 domains (18 of 22, 82%, P<0.001 
versus Genome Aggregation Database common variants) and were associated with similar hypertrophy severity and adverse 
event rates as observed with truncating variants. MyBP-C with variants in the C3, C6, and C10 domains was expressed in rat 
ventricular myocytes. C10 mutant MyBP-C failed to incorporate into myofilaments and degradation rates were accelerated 
by ≈90%, while C3 and C6 mutant MyBP-C incorporated normally with degradation rate similar to wild-type.
CONCLUSIONS: Truncating variants account for 91% of MYBPC3 pathogenic variants and cause similar clinical severity and 
outcomes regardless of location, consistent with locus-independent loss-of-function. Nontruncating MYBPC3 pathogenic 
variants are regionally clustered, and a subset also cause loss of function through failure of myofilament incorporation and 
rapid degradation. Cardiac morphology and clinical outcomes are similar in patients with truncating versus nontruncating 
variants.
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Familial hypertrophic cardiomyopathy (HCM) is an autosomal dominant condition, and pathogenic vari-ants in cardiac MyBP-C (myosin binding protein C; 
encoded by the gene, MYBPC3) are the most common 
cause.1 MyBP-C is a sarcomeric protein that binds both 
actin and myosin and regulates cardiac contractility by 
modulating myofilament sliding velocity.2,3 Because a 
large number of unique MYBPC3 variants have been 
associated with HCM, small, single-center cohorts have 
had limited capacity to systematically analyze genotype-
phenotype relationships, particularly given the marked 
variability in penetrance of MYBPC3-associated HCM.4–7 
Resolving these gaps in knowledge will be critical to fur-
ther personalized risk assessment and management of 
patients with HCM.
Most MYBPC3 pathogenic variants are frameshift, 
nonsense, or splice-site variants that result in prema-
ture termination codons (PTCs). PTC-containing tran-
scripts are targeted for degradation through nonsense 
mediated RNA decay, and hence may cause disease 
through allelic loss of function (resulting in reduced 
levels of MyBP-C). Consistent with allelic insuffi-
ciency, we and others have shown a ≈40% reduction 
in MyBP-C in heart tissue from patients with HCM,8,9 
due to a rate-limiting reduction in MYBPC3 mRNA.10 
These studies support the hypothesis that truncat-
ing variants in MYBPC3 likely exert a similar primary 
effect, independent of the specific variant locus. How-
ever, comparative analyses across the full genotypic 
and phenotypic spectrum of truncating variants have 
not been possible due to the small size of previously 
available cohorts. Distinct from truncating MYBPC3 
variants, nontruncating pathogenic variants (includ-
ing missense and short in-frame deletions/insertion 
variants) account for ≈15% of MYBPC3 HCM. The 
mechanism(s) of MYBPC3 nontruncating pathogenic 
variants are largely unknown, and it is unclear whether 
phenotypic expression or clinical outcomes are differ-
ent in patients carrying missense variants.7,11 A greater 
understanding of the disease-causing mechanism(s) of 
nontruncating MYBPC3 pathogenic variants through 
functional analyses could improve adjudication of vari-
ant pathogenicity and expand the pool of clinically 
actionable gene test results.
Here, we use the largest registry of combined genet-
ics and clinical data for HCM to date, the Sarcomeric 
Human Cardiomyopathy Registry1 (SHaRe), to gener-
ate an adjudicated and comprehensive compendium 
of MYBPC3 variation, analyze regional variation within 
MYBPC3, and correlate clinical phenotypes. We find 
that pathogenic truncating variants are homogeneously 
distributed throughout the gene, in contrast to nontrun-
cating MYBPC3 pathogenic variants that cluster in spe-
cific protein domains. Disease severity is highly variable 
in MYBPC3 HCM, and we show that this variability is 
largely independent of variant location or the specific 
truncating or nontruncating variant based on both dis-
ease severity metrics and clinical outcomes. Finally, we 
experimentally test functional effects of nontruncating 
pathogenic variants in the identified variant-enriched 
domains and identify a subset that exhibit allelic loss of 
function.
METHODS
The methods used are described for purposes of replicating 
the study procedure. Individual patient data will not be made 
available for purposes of reproducing the results. The study 
was independently approved by the institutional review board 
at each center. A detailed methods section is available in the 
Data Supplement.
RESULTS
Clinical Profile of MYBPC3 Mutation HCM
Among these patients with pathogenic MYBPC3 vari-
ants, 1238 (94%) carried single pathogenic variants in 
MYBPC3 without pathogenic variants in other sarco-
mere genes and comprised the primary study group. The 
largest subset of these patients (N=1047, 71%) carried 
truncating MYBPC3 variants (234 unique variants), while 
29% (N=191) had nontruncating variants (22 unique 
variants).
The demographic and clinical profile of patients 
with MYBPC3 pathogenic variants is shown in Table 1. 
The majority (76%) of patients presented in early-mid 
adulthood (age 18–60 years) with a minority of pedi-
atric (13%) or late adulthood (10%) presentations. The 
average age of diagnosis was younger among patients 
with nontruncating pathogenic variants due to a greater 
percentage with pediatric diagnoses (24% versus 
11%, P=0.0001). Maximum left ventricular (LV) wall 
thickness was greater in the relatively small subset of 
pediatric patients with nontruncating variants but was 
similar in other age groups. LV ejection fraction was 
similarly elevated at a young age in both groups and 
declined similarly in later age groups. Left atrial diam-
eter progressively increased to a similar extent with 
increasing age in both truncating and nontruncating 
Nonstandard Abbreviations and Acronyms
HCM hypertrophic cardiomyopathy
LV left ventricle
MyBP-C myosin binding protein C
PTC premature termination codon
SHaRe  Sarcomeric Human Cardiomyopathy 
Registry
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groups (with the single exception of the smaller sized 
group of nontruncating variant patients at age >60; 
N=17). The distributions of maximum wall thickness, 
left atrial size, and age of diagnosis among nontrun-
cating and truncating pathogenic variant cases are 
shown in Figure 1A through 1C. Time to event analysis 
for composite adverse outcomes revealed no differ-
ence between patients with nontruncating or truncat-
ing pathogenic variants (Figure 1D), and this result was 
not different when including probands only (Figure IA 
in the Data Supplement). There were similarly no differ-
ences between the groups for heart failure or ventricu-
lar arrhythmia composite outcomes (not shown).
Morphological Severity and Adverse Events Are 
Similar Across Truncating MYBPC3 Pathogenic 
Variants
If truncating MYBPC3 variants cause allelic insufficiency 
as their primary consequence, then the location of the 
variant within the gene would not be expected to influ-
ence the disease severity. To test this, we categorized 
truncating MYBPC3 pathogenic variants into quartiles by 
5′ to 3′ location and compared morphological markers 
of severity and adverse outcomes. We found no statis-
tically significant difference in maximum wall thickness 
or age-adjusted left atrial diameter among these groups 
(Figure 2A and 2B). Composite adverse events were 
also similar when stratified by variant location quartile 
(Figure 2C) or by truncating variant type (Figure IB in the 
Data Supplement).
Morphological Severity, Adverse Events, and 
Variability in Phenotype Are Similar Among 
Founder and Nonfounder Truncating MYBPC3 
Pathogenic Variants
Several founder truncating pathogenic variants in 
MYBPC3 have a high prevalence among patients with 
HCM. In SHaRe, 4 distinct founder truncating variants 
exist in large numbers, enabling comparison across sub-
groups that share the same primary causative sarcomere 
gene mutation. These founder populations consisted of 
142 individuals with the c.742G>A variant (exonic splice 
variant causing exon skipping and PTC12), 143 with the 
c.2373insG variant (insertion variant causing frameshift 
and PTC),13 67 with the c.2827C>T variant (nonsense 
variant), and 58 with the c.2864_2865del variant (dele-
tion causing frameshift and PTC). LV hypertrophy was 
similar across each of these 4 founder populations and 
the remaining nonfounder truncating variant patients 
(N=638), further supporting that different truncating 
variants exert a similar effect (Figure 2D). Additionally, 
adverse events were similar in each founder population 
compared with patients with nonfounder truncating vari-
ants (Figure 2E).
HCM is known to have broad variance in phenotypic 
severity across individuals. This variance in expressivity 
has been thought to be due to heterogeneity of effect 
size of underlying pathogenic variants, the influence 
of background genetic variation (ie, genetic modifiers), 
and clinical comorbidities.14–17 Taking advantage of the 
founder populations, we compared variances across 
these subgroups each carrying identical pathogenic vari-
ants. As shown in the histogram plot of maximum wall 
thickness in Figure 2F, the 4 founder populations dem-
onstrate similar variance (mean of SDs, 5.96±0.79 mm) 
compared with the remainder of the truncating variant 
population (SD, 5.98 mm; P=NS). Taken together, these 
findings indicate that truncating variants likely exert a 
Table 1. Demographic Characteristics of Patients With 
Truncating and Nontruncating MYBC3 Pathogenic Variants
Nontruncating 
pathogenic  
variant (N=191)
Truncating 
pathogenic  
variant (N=1047) P value
Age at diagnosis, y 34.18±17.98 38.96±16.75 0.0004
Age group at diagnosis 0.0001
 <18 44 (23.66%) 119 (11.41%)  
 18–40 65 (34.95%) 409 (39.21%)  
 40–60 60 (32.26%) 408 (39.12%)  
 >60 17 (9.14%) 107 (10.26%)  
Proband 158 (82.7%) 814 (77.1%) 0.1
Female 74 (38.7%) 399 (37.8%) 0.86
Race 0.15
 European ancestry 166 (93.79%) 939 (92.60%)  
 Asian ancestry 2 (1.13%) 23 (2.27%)  
 African ancestry 1 (0.56%) 29 (2.86%)  
 Other or not reported 6 (3.39%) 17 (1.68%)  
Family history of HCM 108 (56.54%) 590 (55.87%) 0.93
LV maximum wall thickness
 Age <18 21.3+8.1 17.5+7.1 0.01
 Age 18–40 21.2+6.2 21.3+6.1 1
 Age 40–60 20.1+5.1 19.8+5.0 0.99
 Age >60 18.3+4.9 19.4+4.9 0.77
Left atrial diameter
 Age <18 30.7±7.6 33.5±7.7 0.7
 Age 18–40 38.9±8.9 39.6±11.7 0.87
 Age 40–60 42.1±11.1 42.8±10.6 0.87
 Age >60 36.8±13.2 45.7±12.7 0.004
LVOT obstruction 36 (18.8%) 330 (31.5%) 0.004
LV ejection fraction
 Age <18 71.3±6.2% 67.8±7.6% 0.4
 Age 18–40 62.2±8.5% 63.1±10.0% 0.95
 Age 40–60 63.1±11.4% 62.2±9.8% 0.97
 Age >60 61.8±12.1% 61.2±9.7% 0.99
Apical variant 7 (3.7%) 26 (2.4%) 0.32
Morphological parameters were obtained from first echocardiogram at 
a SHaRe site and stratified by age group at the time of the echocardiogram. 
HCM indicates hypertrophic cardiomyopathy; LV, left ventricular; and LVOT, left 
ventricular outflow tract.
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similar primary effect, and the marked variance in disease 
phenotype among truncating variant patients is caused 
by additional genetic and nongenetic factors, indepen-
dent of the driving MYBP3 variant.
Variant Classification and Distribution of 
Truncating and Nontruncating MYBP3 
Pathogenic Variants in HCM
MYBPC3 truncating variant types in SHaRe patients 
consisted of 110 unique insertion/deletion variants, 55 
unique nonsense variants, and 69 unique splice vari-
ants (Table I in the Data Supplement). Classification of 
potential splice variants is complicated by the fact that 
only a portion of splice consensus sites are strictly con-
served. The 69 unique splice pathogenic variants were 
classified through application of the American College 
of Medical Genetics and Genomics Association for 
Molecular Pathology criteria, combined with enrichment 
in SHaRe, prior experimental confirmation, and indepen-
dent experimental confirmation in select cases (Tables I 
and II and Figure II in the Data Supplement). These crite-
ria left a total of 26 of 99 potential intronic variants clas-
sified at variant of unknown significance (VUS) status. 
Six exonic splice variants were identified at the last base 
pair position in their respective exons (donor -1 position), 
4 of which have had prior experimental confirmation of 
splice disruption in human heart tissue.12,18 These splice 
variants (c.655G>C, c.772G>A, c.772G>C, c.1090G>A, 
c.1624G>C, c.1790G>A) were consequently classified 
as truncating—an important distinction since errone-
ous classification as missense variants would impact 
clustering analysis of the nontruncating variants. Com-
parison of our clinical-genetics assignment of variant 
Figure 1. MYBPC3 nontruncating pathogenic variants cause similar phenotypic severity and adverse event rates as truncating 
variants.
A, Distributions in maximum wall thickness demonstrate broad phenotypic variance and similarity between truncating and nontruncating 
MYBPC3 pathogenic variant groups. Data is shown in violin plots with median and interquartile range. B, Average age-adjusted left atrial 
diameter was smaller among nontruncating pathogenic variant carriers. C, Broad variability in disease severity is reflected by range in age 
of diagnosis in both MYBPC3 groups, with a modestly lower average age of diagnosis among nontruncating pathogenic variant carriers. D, 
Kaplan-Meier survival analysis shows no difference in the composite adverse event rate from time of birth between truncating and nontruncating 
pathogenic variant groups. Composite outcome consisted of first occurrence of any of the following: sudden cardiac death, resuscitated 
cardiac arrest, appropriate implantable cardioverter-defibrillator therapy, cardiac transplantation, left ventricle (LV) assist device implantation, LV 
ejection fraction <35%, or New York Heart Association class III/IV symptoms, atrial fibrillation (AF), stroke, or death.
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pathogenicity to the MYBPC3 splice variant prediction 
mini-gene splice assay developed by Ito et al19 dem-
onstrated a high, though not perfect, level of concor-
dance, with 20 out of 23 variants (87%) in agreement 
(Tables I and III in the Data Supplement). Nontruncating 
pathogenic variants were less common than truncating 
variants, with only 22 unique variants meeting criteria 
for pathogenicity, present in a total of 191 patients car-
rying a single sarcomere gene pathogenic variant (15% 
of MYBPC3 pathogenic variant patients). The potential 
pathogenicity of 147 nontruncating VUS’s could not be 
resolved with clinical data from SHaRe.
Figure 2. MYBPC3 truncating pathogenic variants cause similar phenotypic severity regardless of variant locus or type.
A and B, Truncating MYBPC3 variants were categorized by locus quartiles within the gene to examine whether N-terminal or C-terminal 
truncations exert different effect sizes. No difference in extent of hypertrophy (A) or left atrial diameter (B) are observed. C and D, Four 
founder populations within Sarcomeric Human Cardiomyopathy Registry (SHaRe) were compared with determine whether phenotypic 
severity is different in the setting of these 4 distinct truncating variant types (c.742G>A=exonic splice variant, c.2373insG=frameshift, 
c.2827C>T=nonsense, c.2864_2865del=frameshift). No difference was observed either in the variance/distribution of hypertrophy (C) or in 
the magnitude of hypertrophy (D).
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To determine regional variation in the distribution of 
MYBPC3 pathogenic variants, we mapped all unique 
MYBPC3 pathogenic variants in SHaRe by location 
within the coding sequence, stratified by truncating or 
nontruncating variant type (Figure 3). Truncating vari-
ants were dispersed throughout the coding regions of 
the gene without evidence of regional clustering. In addi-
tion, unique truncating variants were similarly prevalent in 
the N-terminus (including a variant that disrupts the start 
codon). In contrast, nontruncating pathogenic variants 
were primarily localized in the C3, C6, and C10 domains 
(18 of 22, 82%)—as compared with nontruncating com-
mon variants in the Genome Aggregation Database that 
were distributed throughout the gene (Figure 1, Tables 
III and IV in the Data Supplement). The C3 domain alone 
accounted for most individuals with MYBPC3 nontrun-
cating variants in SHaRe (177 of 191, 93%). Among 
Genome Aggregation Database common variants, a 
lower percentage (17%, 23 of 135) localized to the C3, 
C6, or C10 domains (P<0.0001 compared with SHaRe).
Experimental Confirmation of Domain Specific 
Effects of MyBP-C Nontruncating Pathogenic 
Variants on Myofilament Incorporation and 
Degradation Rate
While strong evidence supports allelic insufficiency is 
the primary mechanism across the spectrum of truncat-
ing MYBPC3 variants, the mechanism(s) of nontruncat-
ing MYBPC3 pathogenic variants has not been resolved. 
We hypothesized that some nontruncating MYBPC3 
pathogenic variants may also cause loss of function, but 
through lack of normal protein localization or structural 
stability rather than reduced expression. Therefore, we 
first tested whether exogenously expressed MyBP-C 
with nontruncating pathogenic variants incorporates 
normally into the myofilaments. We expressed FLAG-
epitope labeled MyBP-C with or without pathogenic 
nontruncating variants in neonatal rat ventricular myo-
cytes and analyzed localization by immunofluorescence. 
We found that MyBP-C containing representative C3 or 
C6 domain nontruncating variants localized normally to 
the sarcomere A bands while MyBP-C containing C10 
domain nontruncating variants was essentially absent 
from the myofilaments (Figure 4).
A lack of mutant MyBP-C myofilament incorpora-
tion could be either due to perturbation of binding sites 
required for correct localization or protein instability. To 
determine if pathogenic variants in the C10 domain result 
in protein destabilization, we performed cyclohexamide 
pulse-chase experiments using neonatal rat ventricular 
myocytes transduced with FLAG-tagged mutant MyBP-
C for representative variants. Consistent with MyBP-C 
destabilization as a consequence of pathogenic variants 
in the C10 domain, we found a marked 90% reduction in 
protein half-life (Figure 5 and Table 2). In contrast, most 
pathogenic variants in the C3 and C6 domains resulted 
in MyBP-C protein half-lives that were not significantly 
different from wild-type MyBP-C, though the Arg502Trp 
variant resulted in a modest 36% shorter protein half-
life compared with wild-type (P=0.04). Paradoxically, the 
Arg810His variant resulted in a 44% prolonged MyBP-C 
protein half-life compared with wild-type (P=0.008).
DISCUSSION
Despite genetic variants in MYBPC3 being the most 
common cause of familial HCM, identifying geno-
type-phenotype correlations has been elusive, due 
to the large number of individual pathogenic variants 
and small numbers of patients previously available to 
study from single centers. Here, we harness the largest 
cohort of genotyped patients with HCM to comprehen-
sively describe MYBPC3 genetic variation and associ-
ated clinical phenotypes.
A convergent theory of allelic insufficiency from trun-
cating MYBPC3 variants has emerged from human tis-
sue, rodent, and induced pluripotent stem cell model 
systems.8,10,20–22 Reduction in MyBP-C relative to myosin 
alters sliding velocities as actin-myosin sliding reaches 
Figure 3. Distribution of MYBPC3 pathogenic variants, variants of unknown significance, and common Genome Aggregation 
Database (gnomAD) variants relative to MyBP-C (myosin binding protein C) protein domains.
Truncating MYBPC3 pathogenic variants are dispersed homogeneously throughout the gene, while nontruncating pathogenic variants exhibit 
clustering in the C3, C6, and C10 domains (18 of 22, 82%). Nontruncating variants of unknown significance are dispersed throughout the 
gene, as are gnomAD common variants (ie, allele frequency >4×10−5).
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the C-zones, where MyBP-C is specifically present, 
resulting in a more rapid contractile deceleration toward 
peak force development.2,8,10,23 However, clinical-genet-
ics data to confirm this theory have been notably absent. 
Our findings of a homogeneous distribution of HCM-
causing truncating variants throughout MYBPC3, similar 
phenotypic severity across spatial quartiles in the cod-
ing sequence, and similar adverse event rates support 
the theory that disease results from a biologically similar 
loss of function mechanism across truncating variants, as 
opposed to dominant negative consequences from trun-
cated MyBP-C protein (which has not been detectable 
in human heart or cellular models9,10,12). Furthermore, we 
found that 4 founder populations, with distinct truncating 
variants and sizable numbers in SHaRe, exhibit similar 
disease severity and adverse event rates as compared 
with nonfounder truncating variant patients. This result 
extends findings from a single site investigation of the 
Netherlands founder cohort,24 and counters smaller 
series that have suggested less pathogenic effects in 
truncating variant founder cohorts.25,26 A major impli-
cation of these results is that patients with truncating 
MYBPC3 variants would likely derive similar benefit from 
targeted treatment approaches irrespective of the spe-
cific location of the truncating variant.
We further leveraged the truncating variant founder 
populations in SHaRe to investigate the variability in 
expressivity in HCM. HCM exhibits vast genetic and phe-
notypic heterogeneity, which has been a major challenge 
in determining genotype-phenotype relationships.27 We 
found that patients with founder variants had a similar 
distribution of phenotypic features and clinical outcomes 
as nonfounder patients with HCM with truncating vari-
ants. This finding suggests that the variability in disease 
phenotype among MYBPC3 truncating variant carriers 
is not dictated solely by the primary pathogenic variant. 
An important implication of this finding is that additional 
genetic and nongenetic modifiers likely account for the 
broad variance in phenotypic severity among patients 
with MYBPC3 HCM.
Figure 4. Nontruncating MyBP-C (myosin binding protein C) mutant protein localizes to the myofilament for C3 and C6 domain 
mutants but does not incorporate into myofilaments for C10 domain mutants.
To determine whether mutant MyBP-C proteins integrate normally into the myofilaments, both FLAG-tagged control and mutant constructs 
were cloned into an adenoviral vector that was then used to transduce neonatal rat ventricular myocytes (NRVMs). Forty-eight hours following 
transduction, NRVMs were immunofluorescently labeled with an anti-MyBP-C antibody to detect both endogenous and exogenously expressed 
MyBP-C (left column) and an anti-FLAG antibody to detect only the transduced MyBP-C (middle column). This system achieved stable 
integration of FLAG-control MyBP-C into myofilaments (top row) with no FLAG signal detected without viral transduction (second row). 
Nontruncating mutant MyBP-C for C3 and C6 domain pathogenic variants exhibited normal myofilament integration while C10 mutant MyBP-C 
exhibited poor or no myofilament localization.
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We also demonstrate that MYBPC3 nontruncating 
pathogenic variants, accounting for 15% of MYBPC3 
pathogenic variants, generally had a similar phenotypic 
effect as truncating variants. Minor differences between 
the groups included a modestly greater proportion of 
pediatric diagnoses in the nontruncating group and mod-
estly reduced prevalence of LV outflow tract obstruction. 
However, maximal LV wall thickness across all other age 
groups and adverse event rates were highly similar.
Because nontruncating variants are robustly adju-
dicated in SHaRe, we were able to identify strong evi-
dence of domain clustering. We then demonstrated that 
a subgroup of nontruncating pathogenic variants (those 
in the C10 domain) renders the resultant mutant pro-
tein susceptible to rapid degradation, resulting in a loss 
of function mechanism similar to truncating variants. In 
contrast, we show no destabilization in the majority of C3 
and C6 domain mutant proteins, which integrate normally 
in myofilaments. The C3 variant Arg502Trp alters the 
electrostatic properties of the domain, but how this alter-
ation affects MyBP-C function is not known.28 In engi-
neered heart tissue, overexpression of the C3 mutant 
Gly531Arg (not present in SHaRe), caused hypercon-
tractility at low calcium levels and was not able to rescue 
MyBP-C knock-out tissues.29 Further study is required to 
fully elucidate the impact of C3 and C6 pathogenic vari-
ants on contractile function.
In contrast to the clustering evident for pathogenic 
nontruncating variants, VUS’s in MYBPC3 were rela-
tively common in the SHaRe cohort (N=148, 87% of all 
unique MYBPC3 nontruncating variants). Accurate pre-
diction of pathogenicity of sarcomere VUS’s is a major 
challenge for interpretation of genetic testing results 
and determination of the suitability for cascade testing 
in family members. Although we confirmed enrichment 
of nontruncating pathogenic variants in specific MyBP-
C domains, as also shown in an independent cohort 
by Walsh et al,30 the presence of common variants in 
Figure 5. Nontruncating mutant MyBP-C (myosin binding protein C) degradation rates measured by cyclohexamide pulse chase 
demonstrate rapid degradation for C10 domain nontruncating mutant MyBP-C.
To determine whether nontruncating MYBPC3 pathogenic variants alter protein stability, neonatal rat ventricular myocytes were transduced 
with adenoviral constructs expressing wild-type (WT) control and nontruncating mutant MyBP-C. Cyclohexamide was administered at 0, 
30 min, 1 h, 3 h, 6 h, and 12 h to inhibit protein synthesis and MyBP-C was measured (see Methods in the Data Supplement). Data from 
2 or more independent experiments performed in quadruplicate were fit to a first order exponential decay curve. The same control data 
(from FLAG-labeled wild-type expressed MyBP-C) is depicted on each graph (A–C). A and B, C3 and C6 mutant MyBP-C demonstrates 
similar degradation rates as control. C, C10 mutant MyBP-C demonstrates rapid degradation compared with control. Data is represented as 
mean±SEM. The calculated half-lives with 95% CIs are shown in Table 2.
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Genome Aggregation Database in these same domains 
should preclude a complete reliance on a generalized 
domain-centric approach to determine variant pathoge-
nicity. Nevertheless, the presence of a variant in the C3, 
C6, or C10 domains in a patient with HCM increases 
the probability of pathogenicity and could be used as a 
supportive criterion with other clinical variables in vari-
ant classification. Moreover, identifying VUS’s that cause 
protein instability could be a useful strategy for functional 
annotation of variants.
Several limitations to our study should be considered. 
This was a retrospective, observational study. Although we 
analyzed by far the largest cohort of patients with HCM 
with MYBPC3 pathogenic variants to date, the study may 
be underpowered to detect small differences in pheno-
type severity or adverse events between groups. In addi-
tion, we analyzed pathogenic variant carriers in groups 
based on variant type and location, but further subdivi-
sion to individual pathogenic variants was only feasible 
for the founder subpopulations. As such, differences in 
effect size for specific pathogenic variants, particularly 
in the case of the nontruncating variants, could still exist. 
Both the SHaRe population and Genome Aggregation 
Database populations predominantly consist of individu-
als from European ancestry. Although these attributes 
lend confidence to the calculation of the odds ratios for 
HCM-associated versus common population variants 
reported here, the results are not necessarily repre-
sentative of genetic variation in other ancestries. Relat-
edly, the SHaRe population has a greater proportion of 
patients with HCM with truncating founder variants due 
to inclusion of certain European sites (the Netherlands, 
Italy). Lastly, we strategically focused experimental test-
ing of nontruncating pathogenic variants to the impact 
on protein stability and only examined a subset of repre-
sentative variants. Future work will be needed to further 
resolve the functional effects of pathogenic nontruncat-
ing MYBPC3 variants that do not destabilize the protein 
structure and extending these analyses more compre-
hensively across MYBPC3 nontruncating variants.
In conclusion, we leverage the largest cohort of 
patients with MYBPC3 pathogenic variants to date 
to develop a compendium of benign, pathogenic, and 
uncertain MYBPC3 variants and identify genotype-phe-
notype correlations. Our results demonstrate that pheno-
typic severity and clinical outcomes are similar across the 
range of MYBPC3 pathogenic variant carriers, without 
obvious associations based on the location of truncating 
variants, founder, or nonfounder truncating variant carri-
ers, or truncating versus nontruncating variants. These 
findings highlight the need to identify additional back-
ground genetic and nongenetic modifiers that influence 
the broadly variable HCM disease phenotype. In addition, 
we show that nontruncating pathogenic variants cluster 
in particular MyBP-C domains, with those variants in the 
C10 domain exhibiting protein destabilization leading to 
loss of function, in contrast to a second subset exhibiting 
normal myofilament incorporation and stability.
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Table 2. Nontruncating Mutant MyBP-C Degradation 
Rates Measured by Cyclohexamide Pulse Chase
Adenoviral treatment Half life, h 95% CI P value
Wild-type control 5.06 4.15–6.50 …
Arg495Gln (C3) 5.50 3.95–9.06 0.72
Arg502Trp (C3) 3.24 2.51–4.56 0.044
Phe503Leu (C3) 5.82 4.34–8.81 0.51
Trp792Arg (C6) 3.41 2.66–5.04 0.083
Arg810His (C6) 8.92 6.46–14.40 0.008
Leu1238Pro (C10 0.27 0.16–0.88 P<0.0001
Gly1248-Cys1253 
duplication (C10)
0.43 0.36–0.55 P<0.0001
Asn1257Lys (C10 0.29 0.25–0.35 P<0.0001
MyBP-C indicates myosin binding protein C.
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